Evaxion Biotech A/S (NASDAQ:EVAX) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Evaxion Biotech A/S (NASDAQ:EVAX) in a research report sent to investors on Wednesday morning,Benzinga reports. HC Wainwright currently has a $14.00 price objective on the stock.

Separately, Lake Street Capital lowered their price target on shares of Evaxion Biotech A/S from $35.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, February 4th.

Evaxion Biotech A/S Stock Up 1.8 %

Shares of NASDAQ EVAX opened at $1.69 on Wednesday. Evaxion Biotech A/S has a 52-week low of $1.61 and a 52-week high of $22.05. The firm has a market capitalization of $1.98 million, a price-to-earnings ratio of -1.17 and a beta of -0.25. The stock has a 50 day moving average price of $2.43 and a 200 day moving average price of $6.94. The company has a debt-to-equity ratio of 7.99, a quick ratio of 2.80 and a current ratio of 1.00.

Evaxion Biotech A/S (NASDAQ:EVAX) last posted its quarterly earnings results on Tuesday, April 1st. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.19. The firm had revenue of $0.12 million for the quarter, compared to the consensus estimate of $1.66 million. Sell-side analysts expect that Evaxion Biotech A/S will post -0.15 earnings per share for the current year.

Institutional Trading of Evaxion Biotech A/S

A hedge fund recently bought a new stake in Evaxion Biotech A/S stock. Catalina Capital Group LLC acquired a new stake in Evaxion Biotech A/S (NASDAQ:EVAX) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 34,864 shares of the company’s stock, valued at approximately $29,000. Catalina Capital Group LLC owned about 2.98% of Evaxion Biotech A/S as of its most recent SEC filing. Hedge funds and other institutional investors own 11.04% of the company’s stock.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.